An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women

Ali, Mohamed; Chen, Hsin‐Yuan; Chiang, Yi‐Fen; Badary, Osama A.; Hsia, Shih Min; Al-Hendy, Ayman

doi:10.1080/14656566.2022.2030705

Cited by 6 publications

(2 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 57 Further, recent reports suggest that the combination of relugolix/oestradiol/norethisterone acetate (NETA) is well tolerated and effective in treating HMB associated with uterine fibroids. 58 , 59 …”

Section: Reviewmentioning

confidence: 99%

Effect of norethisterone dose and duration in the management of abnormal uterine bleeding: a narrative review and case report

Boruah,

Banerjee,

Bhardwaj

et al. 2024

DIC

View full text Add to dashboard Cite

Abnormal uterine bleeding (AUB) is an acute/chronic variation in the normal menstrual cycle that affects adolescents, women of reproductive age and perimenopausal women. AUB affects approximately 3–30% of reproductive-aged women worldwide, and reduces their quality of life and productivity whilst increasing the overall healthcare burden. Its management requires thorough medical evaluation and individualized treatment. Depending on the severity and cause of AUB, its treatment ranges from lifestyle modifications and hormonal therapies to more invasive procedures or surgery. Although hormonal therapy is the preferred first-line measure in AUB, the available pharmacological options have various adverse effects. There exists a need for safer and more efficient treatment regimens with high patient compliance to effectively treat AUB. Norethisterone, also known as norethindrone, is a widely used synthetic analogue of progestogen. Controlled release formulations of norethisterone/ norethisterone acetate help maintain constant drug levels in the blood and exert minimal side-effects; therefore, they are promising therapeutic agents for effective AUB management. The present review summarizes the epidemiology and diagnosis of AUB, with a focus on the safety, efficacy and tolerability of norethisterone/ norethisterone acetate in AUB management. We also report a case of AUB in a 40-year-old woman, who was treated with NETA tablets. The treatment resulted in favourable outcomes, and patient satisfaction.

show abstract

Section: Reviewmentioning

confidence: 99%

Effect of norethisterone dose and duration in the management of abnormal uterine bleeding: a narrative review and case report

Boruah,

Banerjee,

Bhardwaj

et al. 2024

DIC

View full text Add to dashboard Cite

show abstract

“…Relugolix was moreover registered also in Japan, for uterine leiomyoma (2019) and it was also approved this year in the European Union for the treatment of advanced hormone-sensitive prostate cancer. In addition, Myovant Sciences proved the beneficial effect of the co-administration of estradiol, norethisterone and relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids (uterine leiomyoma) ( Ali et al, 2022 ). This drug association aims to optimize estradiol levels to achieve the long-term benefit of relugolix, while mitigating the side effects from a low-estrogen state.…”

Section: Urea-based Anticancer Drugsmentioning

confidence: 99%

Urea-based anticancer agents. Exploring 100-years of research with an eye to the future

et al. 2022

View full text Add to dashboard Cite

Suramin was the first urea-based drug to be approved in clinic, and in the following century a number of milestone drugs based on this scaffold were developed. Indeed, urea soon became a privileged scaffold in medicinal chemistry for its capability to establish a peculiar network of drug−target interactions, for its physicochemical properties that are useful for tuning the druggability of the new chemical entities, and for its structural and synthetic versatility that opened the door to numerous drug design possibilities. In this review, we highlight the relevance of the urea moiety in the medicinal chemistry scenario of anticancer drugs with a special focus on the kinase inhibitors for which this scaffold represented and still represents a pivotal pharmacophoric feature. A general outlook on the approved drugs, recent patents, and current research in this field is herein provided, and the role of the urea moiety in the drug discovery process is discussed form a medicinal chemistry standpoint. We believe that the present review can benefit both academia and pharmaceutical companies’ medicinal chemists to prompt research towards new urea derivatives as anticancer agents.

show abstract

Current and Emerging Treatment Options for Uterine Fibroids

Ali,

Ciebiera,

Wlodarczyk

et al. 2023

Drugs

View full text Add to dashboard Cite

An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women

Cited by 6 publications

References 53 publications

Effect of norethisterone dose and duration in the management of abnormal uterine bleeding: a narrative review and case report

Effect of norethisterone dose and duration in the management of abnormal uterine bleeding: a narrative review and case report

Urea-based anticancer agents. Exploring 100-years of research with an eye to the future

Current and Emerging Treatment Options for Uterine Fibroids

Contact Info

Product

Resources

About